for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vanda Pharmaceuticals Inc.

VNDA.OQ

Latest Trade

13.21USD

Change

-0.29(-2.15%)

Volume

468,729

Today's Range

13.18

 - 

13.58

52 Week Range

11.88

 - 

33.39

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.50
Open
13.49
Volume
468,729
3M AVG Volume
15.40
Today's High
13.58
Today's Low
13.18
52 Week High
33.39
52 Week Low
11.88
Shares Out (MIL)
53.27
Market Cap (MIL)
703.75
Forward P/E
39.11
Dividend (Yield %)
--

Next Event

Vanda Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Vanda Pharmaceuticals Says Received Complete Response Letter From U.S. FDA

Vanda Pharmaceuticals Reports Qtrly Earnings Per Share $0.21

Vanda Pharmaceuticals FDA Update For Hetlioz In The Treatment Of Jet Lag Disorder

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

Industry

Biotechnology & Drugs

Contact Info

2200 Pennsylvania Ave NW Ste 300E

+1.202.7343400

http://www.vandapharma.com/

Executive Leadership

H. Thomas Watkins

Independent Chairman of the Board

Mihael Hristos Polymeropoulos

President, Chief Executive Officer, Director

James Patrick Kelly

Chief Financial Officer, Executive Vice President, Treasurer

Gian Piero Reverberi

Senior Vice President, Chief Compliance Officer

Timothy I. Williams

Senior Vice President, General Counsel, Secretary

Key Stats

2.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.2K

2018

0.2K

2019(E)

0.2K
EPS (USD)

2016

-0.410

2017

-0.350

2018

0.480

2019(E)

0.338
Price To Earnings (TTM)
25.49
Price To Sales (TTM)
3.37
Price To Book (MRQ)
2.37
Price To Cash Flow (TTM)
22.40
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
10.05
Return on Equity (TTM)
8.42

Latest News

Humane Society backs Vanda's animal drug study case against FDA

The Humane Society of the United States is backing Vanda Pharmaceuticals Inc's fight against a U.S. Food and Drug Administration requirement that it conduct a study of a drug's risks to humans using dogs who would be euthanized at the end of the study.

Vanda loses bid to proceed with drug trial while FDA reconsiders hold

A federal judge ruled on Thursday that Vanda Pharmaceuticals Inc could not proceed with a human clinical trial for its gastrointestinal drug tradipitant while the U.S. Food and Drug Administration weighs requiring months of additional animal toxicity testing.

FDA fights Vanda bid to lift partial hold on human drug trial

The Food and Drug Administration is urging a judge to not allow Vanda Pharmaceuticals Inc to proceed with a human clinical drug trial while the agency reconsiders whether the drugmaker must also conduct a study on dogs who would need to be euthanized at the end of the trial.

Drugmaker Vanda sues FDA over required animal drug study

Biopharmaceutical company Vanda Pharmaceuticals Inc has sued the U.S. Food and Drug Administration, saying the regulator is forcing it to unnecessarily conduct a study of a drug it is developing on dogs who would need to be euthanized at it conclusion.

BRIEF-Vanda Pharmaceuticals Says Hetlioz Is Effective In Treating Jet Lag During Transatlantic Travel

* HETLIOZ® (TASIMELTEON) EFFECTIVE IN TREATING JET LAG DURING TRANSATLANTIC TRAVEL

BRIEF-Vanda Pharmaceuticals Inc Reports Qtrly EPS Of $0.06

* VANDA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

Patent on Vanda schizophrenia drug upheld by appeals court

A federal appeals court on Friday ended a bid by West-Ward Pharmaceuticals Corp to invalidate a patent on Vanda Pharmaceutical Inc's schizophrenia drug Fanapt and bring a lower-cost generic version to market.

BRIEF-Vanda Pharmaceuticals Wins Appeal Case On Fanapt

* U.S. FEDERAL COURT AFFIRMED U.S. COURT'S DECISION THAT WEST WARD PHARMACEUTICALS INFRINGED CO'S U.S. '610 PATENT FOR FANAPT

BRIEF-Vanda Pharmaceuticals Gets Paragraph IV Certification Notice For Generic Version Of Hetlioz Capsule

* VANDA PHARMACEUTICALS - ON MARCH 23, GOT PARAGRAPH IV CERTIFICATION NOTICE LETTER REGARDING ANDA BY TEVA FOR GENERIC VERSION OF 20MG HETLIOZ CAPSULE

BRIEF-Vanda Pharma Prices Public Offering Of Common Stock

* SALE OF 5.5 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING AT $17.00 PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Vanda Pharmaceuticals Inc. Proposes Public Offering Of Common Stock

* VANDA PHARMACEUTICALS INC. PROPOSES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Vanda's Hetlioz Demonstrates Efficacy To Treat Jet Lag Disorder

* HETLIOZ® (TASIMELTEON) DEMONSTRATES EFFICACY TO TREAT JET LAG DISORDER IN AN 8 HOUR PHASE ADVANCE CLINICAL STUDY

BRIEF-Vanda Pharmaceuticals Qtrly Net Loss Per Share $0.04

* VANDA PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Vanda receives negative opinion for marketing authorization from the European Medicines Agency

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia

BRIEF-Vanda Pharmaceuticals posts qtrly ‍net loss of $0.10​/share

* Qtrly net loss per share $0.10 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Vanda Pharmaceuticals reached a pricing agreement with the German National Association of Statutory Health Insurance Funds

* Vanda Pharmaceuticals - On Oct 17, co reached a pricing agreement with the German National Association of Statutory Health Insurance Funds

BRIEF-Vanda Pharmaceutical ‍announced results from study of Tradipitant as a treatment of chronic pruritus

* Vanda Pharmaceuticals Inc - announced results from randomized phase ii clinical study of Tradipitant as a monotherapy in treatment of chronic pruritus

BRIEF-Vanda Pharmaceuticals qtrly ‍net loss per share $0.03​

* Vanda Pharmaceuticals Inc - total net product sales were $42.1 million in Q2 of 2017

BRIEF-Vanda receives negative opinion for marketing authorization from the EMA on Fanaptum

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on Fanaptum™ for the treatment of schizophrenia

BRIEF-Armistice Capital Llc reports 5.1 pct passive stake in Vanda Pharmaceuticals Inc

* Armistice Capital Llc reports a 5.1 percent passive stake in Vanda Pharmaceuticals Inc as of June 7 - sec filing Source text for Eikon: (http://bit.ly/2rwELbT) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up